Anorexia, Body Dysmorphic Disorders
Conditions
Keywords
anorexia nervosa, opioid receptors, Positron emission tomography (PET), diprenorphine
Brief summary
The place of opioid system in anorexia nervosa (AN) physiopathology is still unclear. Conflicting results were published on cerebral spinal fluid or peripheral levels in anorexia nervosa. However, no data have been reported on opioid cerebral activity. Diprenorphine is a ligand with non-selective binding to opiate receptors µ, κ and δ capable to assess the interaction between endogenous opioids and their receptors.
Interventions
DRUGPositron Emission Tomography using [11C]diprenorphine
PET using \[11C\]diprenorphine
Sponsors
Ministry of Health, France
Centre Hospitalier Universitaire de Saint Etienne
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* AN patients DSM IV criteria including amenorrhea BMI \< 17.5 kg/m² and abnormal nutritional markers Group 1 (N=15) : long period of / recurrent weight loss (\> 2 yrs) Group 2 (N=15) : recent weight loss (6 to 12 months) * Recovered AN patients History of AN Weight recovery and BMI \> 18.5 kg/m², stable for at least 12 months Normal nutritional markers Group 1 (N=15) : menses recovery after bodyweight stabilization Group 2 (N=15) : long persistence of amenorrhea (\> 12 months) despite weight recovery * Healthy volunteers (N=15) BMI between 18.5 and 25 kg/m², normal nutritional markers, absence of psychiatric or organic pathology * For all subjects Women 18-35 yrs Written and sign consent Affiliation to health insurance
Exclusion criteria
* History of heart failure * Psychotropic treatment , antiepileptics * Ongoing or suspected pregnancy, positive beta HCG test before brain imaging * Intense physical activity * Constrains for MRI (ferromagnetic implants or claustrophobia) * Refusal to be informed in case of incidentaloma revealed by brain imaging * Refusal for written consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| [11C]diprenorphine binding potential | week 2 | Value of \[11C\]diprenorphine binding potential (BP) in predefined brains regions \[11C\] diprenorphine BP will be evaluated by brain positron emission tomography |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation [11C]diprenorphine binding potential | week 2 | Correlation between \[11C\]diprenorphine binding potential and plasma endogenous opioid levels |
Countries
France
Outcome results
None listed